Clinical Trials Browser

Phase 2 × Lymphoma × polatuzumab vedotin × Clear all

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05410418 2025-12-15

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell